コギソ トモミ   KOGISO Tomomi
  小木曽 智美
   所属   医学部 医学科(東京女子医科大学病院)
   職種   講師
論文種別 原著
言語種別 英語
査読の有無 査読なし
表題 Predictors of liver cirrhosis and hepatocellular carcinoma among perioperative survivors of the Fontan operation.
掲載誌名 正式名:Heart (British Cardiac Society)
略  称:Heart
ISSNコード:1468201X/13556037
掲載区分国外
巻・号・頁 109(4),pp.276-282
著者・共著者 INUZUKA Ryo, NII Masaki, INAI Kei, SHIMADA Eriko, SHINOHARA Tokuko, KOGISO Tomomi, ONO Hiroshi, OTSUKI Shin-Ichi, KURITA Yoshihiko, TAKEDA Atsuhito, HIRONO Keiichi, TAKEI Kota, YASUKOHCHI Satoshi, YOSHIKAWA Tadahiro, FURUTANI Yoshiyuki, SHINOZAKI Tomohiro, MATSUYAMA Yutaka, SENZAKI Hideaki, TOKUSHIGE Katsutoshi, NAKANISHI Toshio
発行年月 2023/01
概要 OBJECTIVE:Fontan-associated liver disease (FALD) is widely recognised as a common complication in patients long after the Fontan operation. However, data on the predictors of FALD that can guide its screening and management are lacking. The present study aimed to identify the predictors of liver cirrhosis (LC) and hepatocellular carcinoma (HCC) in post-Fontan patients.METHODS:This was a multi-institutional retrospective cohort study. Clinical data of all perioperative survivors of Fontan operation before 2011 who underwent postoperative catheterisation were collected through a retrospective chart review.RESULTS:A total of 1117 patients (538 women, 48.2%) underwent their first Fontan operation at a median age of 3.4 years. Postoperative cardiac catheterisation was conducted at a median of 1.0 year. During a median follow-up period of 10.3 years, 67 patients (6.0%) died; 181 (16.2%) were diagnosed with liver fibrosis, 67 (6.0%) with LC, 54 (4.8%) with focal nodular hyperplasia and 7 (0.6%) with HCC. On multivariable analysis, high central venous pressure (CVP) (HR, 1.28 (95% CI 1.01 to 1.63) per 3 mm Hg; p=0.042) and severe atrioventricular valve regurgitation (HR, 6.02 (95% CI 1.53 to 23.77); p=0.010) at the postoperative catheterisation were identified as independent predictors of LC/HCC.CONCLUSIONS:Patients with high CVP and/or severe atrioventricular valve regurgitation approximately 1 year after the Fontan operation are at increased risk of developing advanced liver disease in the long term. Whether therapeutic interventions to reduce CVP and atrioventricular valve regurgitation decrease the incidence of advanced liver disease requires further elucidation.
DOI 10.1136/heartjnl-2022-320940
PMID 35768191